Stock Events

Stock Events

BioMark Diagnostics 

€0.2780
0
+€0.01+5.3%Friday 20:03

Statistics

Day High
0.278
Day Low
0.26
52W High
0.42
52W Low
0.191
Volume
0
Avg. Volume
0
Mkt Cap
29.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-2,450.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37,304.35Revenue
-914,057.89Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.86B
Guardant Health focuses on liquid biopsies and cancer diagnostics, directly competing in BioMark's market of early cancer detection.
Fulgent Genetics
FLGT
Mkt Cap591.03M
Fulgent Genetics offers extensive genetic testing, which is crucial for personalized cancer therapies, overlapping with BioMark's diagnostic solutions.
Illumina
ILMN
Mkt Cap35.63B
Illumina provides genomic sequencing solutions that are foundational to cancer research and diagnostics, impacting the same market as BioMark.
Qiagen NV
QGEN
Mkt Cap9.24B
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing systems that aid in understanding cancer genetics, competing in the broader diagnostics market.
Bionano Genomics
BNGO
Mkt Cap16.07M
Bionano Genomics focuses on genomic analysis, including cancer research, which aligns with BioMark's focus on diagnostic solutions.
Myriad Genetics
MYGN
Mkt Cap434.25M
Myriad Genetics specializes in molecular diagnostic tests that include cancer screenings, directly competing with BioMark's offerings.

About

BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.
Show More
CEO
Rashid Ahmed Maula Bux
Employees
9
Country
Canada
ISIN
CA09073K1084
WKN
000A12EKB

Listings

STU
DE
20B.STU
OTC Link
US
BMKDF
F
DE
20B.F
CN
CA
BUX.CN

0 Comments

Share your thoughts

FAQs

What is BioMark Diagnostics stock price today?▼
The current price of 20B.STU is €0.28 EUR — it has increased by +5.3% in the past 24 hours. Watch BioMark Diagnostics stock price performance more closely on the chart.
What is BioMark Diagnostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange BioMark Diagnostics stocks are traded under the ticker 20B.STU.
Is BioMark Diagnostics stock price growing?▼
20B.STU stock has risen by +6.11% compared to the previous week, the month change is a -14.72% fall, over the last year BioMark Diagnostics has showed a +40.4% increase.
What is BioMark Diagnostics market cap?▼
Today BioMark Diagnostics has the market capitalization of 29.6M
What is BioMark Diagnostics revenue for the last year?▼
BioMark Diagnostics revenue for the last year amounts to 37,304.35 EUR.
What is BioMark Diagnostics net income for the last year?▼
20B.STU net income for the last year is -914,057.89 EUR.
How many employees does BioMark Diagnostics have?▼
As of November 2, 2026, the company has 9 employees.
In which sector is BioMark Diagnostics located?▼
BioMark Diagnostics operates in the Health & Wellness sector.
When did BioMark Diagnostics complete a stock split?▼
BioMark Diagnostics has not had any recent stock splits.
Where is BioMark Diagnostics headquartered?▼
BioMark Diagnostics is headquartered in Richmond, Canada.